Suchergebnisse

This works is at: 5th International Conference on Corpus Linguistics (CILC2013), took place 2013, March 14-16, in Alicante (Spain). Conference web site: http://web.ua.es/en/cilc2013/ ; Natural language processing of pharmacological texts includes recognition of drug names and extraction of relationships between them. To this purpose, pharmacological annotated corpora are required. These corpora are usually semantically annotated by domain experts. However, other linguistic aspects should be considered to ensure the quality and consistency of the annotation. This paper introduces several linguistic phenomena affecting the annotation of both drug named entities and drug-drug interaction relationships that arose during the annotation process of the DDI corpus. The detailed documentation of these issues and the decisions on them will improve the quality of the annotated corpus and its usefulness for other researchers or users ; This work was supported by the Regional Government of Madrid under the Research Network MA2VICMR [S2009/TIC-1542] and by the Spanish Ministry of Economy under the project MULTIMEDICA [TIN2010-20644- C03-01]. ; Publicado

AbstractConduct disorder is one of the most common disorders in children and adolescents, and yet we know little about its cause and treatment.

In recent years the cost of drug development has increased the demands on efficiency in the selection of suitable drug candidates. Biomarkers for efficacy and safety could be a plausible strategy to improve this selection process. In the present work, we focus on the study and evaluation of different physiological variables as biomarkers for pharmacological activity. We proposed three different approaches using multivariate and univariate techniques. We note that even though one could argue that the multivariate procedure is more powerful than the other alternatives, the univariate methods also offer a great flexibility to answer interesting scientific questions. The three approaches were used to analyze a crossover study involving an opioid antagonist. ; Ariel Alonso and Geert Molenberghs gratefully acknowledge financial support from the Interuniversity Attraction Pole Research Network P6/03 of the Belgian Government (Belgian Science Policy). All authors are grateful to Eli Lilly & Company for graciously providing the data.

We investigated tobacco industry documents and other sources for evidence of possible pharmacological and chemical effects of tobacco additives.